Top

Clinical Reviews in Allergy & Immunology

Published in:

01-10-2013

Use of Mesenchymal Stem Cells (MSC) in Chronic Inflammatory Fistulizing and Fibrotic Diseases: a Comprehensive Review

Authors: Jan Voswinkel, Sabine Francois, Jean-Marc Simon, Marc Benderitter, Norbert-Claude Gorin, Mohamad Mohty, Loïc Fouillard, Alain Chapel

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2013

Abstract

Mesenchymal stem cells (MSC), multipotent adult stem cells, feature the potential to regenerate tissue damage and, in parallel, inhibit inflammation and fibrosis. MSC can be safely transplanted in autologous and allogeneic ways as they are non-immunogenic, and consequently represent a therapeutic option for refractory connective tissue diseases, fibrosing diseases like scleroderma and fistulizing colitis like in Crohn’s disease. Actually, there are more than 200 registered clinical trial sites for evaluating MSC therapy, and 22 are on autoimmune diseases. In irradiation-induced colitis, MSC accelerate functional recovery of the intestine and dampen the systemic inflammatory response. In order to provide rescue therapy for accidentally over-irradiated prostate cancer patients who underwent radiotherapy, allogeneic bone marrow-derived MSC from family donors were intravenously infused to three patients with refractory and fistulizing colitis resembling fistulizing Crohn’s disease. Systemic MSC therapy of refractory irradiation-induced colitis was safe and effective on pain, diarrhoea, hemorrhage, inflammation and fistulization accompanied by modulation of the lymphocyte subsets towards an increase of T regulatory cells and a decrease of activated effector T cells. The current data indicate that MSC represent a promising alternative strategy in the treatment of various immune-mediated diseases. Encouraging results have already been obtained from clinical trials in Crohn’s disease and SLE as well as from case series in systemic sclerosis. MSC represent a safe therapeutic measure for patients who suffer from chronic and fistulizing colitis. These findings are instructional for the management of refractory inflammatory bowel diseases that are characterized by similar clinical and immunopathological features.

Djouad F, Bony C, Haupl T et al (2005) Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res Ther 7:R1304–R1315PubMedCrossRef

De Bari C, Dell’Accio F, Luyten FP (2001) Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum 44(1):85–95PubMedCrossRef

Noel D, Caton D, Roche S et al (2008) Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 314:1575–1584PubMedCrossRef

Fickert S, Fiedler J, Brenner RE (2003) Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. Osteoarthr Cartil 11:790–800PubMedCrossRef

Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11–20PubMedCrossRef

Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75(3):389–397PubMedCrossRef

Klyushnenkova E, Mosca JD, Zernetkina V et al (2005) T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12:47–57PubMedCrossRef

Rasmusson I, Ringden O, Sundberg B, Le Blanc K (2003) Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76:1208–1213PubMedCrossRef

Rasmusson I (2006) Immune modulation by mesenchymal stem cells. Exp Cell Res 312:2169–2179PubMedCrossRef

10.

Tokoyoda K, Zehentmeier S, Hegazy AN et al (2009) Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 30:721–730PubMedCrossRef

11.

Chen L, Tredget EE, Wu PY, Wu Y (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3:e1886PubMedCrossRef

12.

Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815–1822PubMedCrossRef

13.

Nemeth K, Leelahavanichkul A, Yuen PS et al (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15:42–49PubMedCrossRef

14.

Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L (2009) MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113:6576–6583PubMedCrossRef

15.

Djouad F, Charbonnier LM, Bouffi C et al (2007) Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25:2025–2032PubMedCrossRef

16.

Jiang XX, Zhang Y, Liu B et al (2005) Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120–4126PubMedCrossRef

17.

Ren G, Su J, Zhang L et al (2009) Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27:1954–1962PubMedCrossRef

18.

Sato K, Ozaki K, Oh I et al (2007) Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109:228–234PubMedCrossRef

19.

Nasef A, Mathieu N, Chapel A et al (2007) Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84:231–237PubMedCrossRef

20.

Nasef A, Zhang YZ, Mazurier C et al (2009) Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol 31:9–19PubMedCrossRef

21.

Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A (2007) Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92:881–888PubMedCrossRef

22.

Parekkadan B, Tilles AW, Yarmush ML (2008) Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 26:1913–1919PubMedCrossRef

23.

Zappia E, Casazza S, Pedemonte E et al (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106:1755–1761PubMedCrossRef

24.

Zhou H, Jin Z, Liu J, Yu S, Cui Q, Yi D (2008) Mesenchymal stem cells might be used to induce tolerance in heart transplantation. Med Hypotheses 70:785–787PubMedCrossRef

25.

Haniffa MA, Wang XN, Holtick U et al (2007) Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 179:1595–1604PubMed

26.

Corcione A, Benvenuto F, Ferretti E et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367–372PubMedCrossRef

27.

Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M (2009) Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 60:1006–1019PubMedCrossRef

28.

Malgieri A, Kantzari E, Patrizi MP, Gambardella S (2010) Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med 3:248–26PubMed

29.

Voswinkel, J., and Chapel, A. (2012). Mesenchymal stem cells and rheumatism: state of the art. Z Rheumatol.

30.

Beggs KJ, Lyubimov A, Borneman JN et al (2006) Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 15:711–721PubMedCrossRef

31.

Le Blanc K, Ringden O (2007) Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 262:509–525PubMedCrossRef

32.

Rubio D, Garcia-Castro J, Martin MC et al (2005) Spontaneous human adult stem cell transformation. Cancer Res 65:3035–3039PubMed

33.

Tarte K, Gaillard J, Lataillade JJ et al (2010) Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115:1549–1553PubMedCrossRef

34.

Bernardo ME, Zaffaroni N, Novara F et al (2007) Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67:9142–9149PubMedCrossRef

35.

Liang J, Zhang H, Hua B et al (2010) Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 69:1423–1429PubMedCrossRef

36.

Sun L, Wang D, Liang J et al (2010) Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62:2467–2475PubMedCrossRef

37.

Dryden GW (2009) Overview of stem cell therapy for Crohn’s disease. Expert Opin Biol Ther 9:841–847PubMedCrossRef

38.

Dryden GW Jr (2009) Overview of biologic therapy for Crohn’s disease. Expert Opin Biol Ther 9:967–974PubMedCrossRef

39.

Ditschkowski M, Einsele H, Schwerdtfeger R et al (2003) Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 75:1745–1747PubMedCrossRef

40.

Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA (2005) A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416–1423PubMedCrossRef

41.

Garcia-Olmo D, Herreros D, Pascual I et al (2009) Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 52:79–86PubMedCrossRef

42.

Garcia-Olmo D, Herreros D, Pascual M et al (2009) Treatment of enterocutaneous fistula in Crohn’s disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis 24:27–30PubMedCrossRef

43.

Garcia-Olmo D, Herreros D, De-La-Quintana P et al (2010) Adipose-derived stem cells in Crohn’s rectovaginal fistula. Case Report Med 2010:961758

44.

Duijvestein M, Vos AC, Roelofs H et al (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut 59:1662–1669PubMedCrossRef

45.

Lazebnik LB, Konopliannikov AG, Kniazev OV et al (2010) Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases. Ter Arkh 82:38–43PubMed

46.

Ciccocioppo R, Bernardo ME, Sgarella A et al (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulizing Crohn’s disease. Gut 60:788–798PubMedCrossRef

47.

Cipriani P, Guiducci S, Miniati I et al (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56:1994–2004PubMedCrossRef

48.

Larghero J, Farge D, Braccini A et al (2008) Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 67:443–449PubMedCrossRef

49.

Keyszer G, Christopeit M, Fick S et al (2011) Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum 63:2540–2542PubMedCrossRef

50.

Deeg HJ (2007) How I treat refractory acute GVHD. Blood 109:4119–4126PubMedCrossRef

51.

Ringden O, Uzunel M, Rasmusson I et al (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81:1390–1397.52PubMedCrossRef

52.

Le Blanc K, Frassoni F, Ball L et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579–1586PubMedCrossRef

53.

Potten CS, Owen G, Roberts SA (1990) The temporal and spatial changes in cell proliferation within the irradiated crypts of the murine small intestine. Int J Radiat Biol 57:185–199PubMedCrossRef

54.

Gaugler MH, Vereycken-Holler V, Squiban C, Vandamme M, Vozenin-Brotons MC, Benderitter M (2005) Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res 163:479–487PubMedCrossRef

55.

Milliat F, Francois A, Isoir M et al (2006) Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages. Am J Pathol 169:1484–1495PubMedCrossRef

56.

Paris F, Fuks Z, Kang A et al (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293–297PubMedCrossRef

57.

Zhang J, Gong JF, Zhang W, Zhu WM, Li JS (2008) Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice. J Biomed Sci 15:585–594PubMedCrossRef

58.

Semont A, Francois S, Mouiseddine M et al (2006) Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury. Adv Exp Med Biol 585:19–30PubMedCrossRef

59.

Kudo K, Liu Y, Takahashi K et al (2010) Transplantation of mesenchymal stem cells to prevent radiation-induced intestinal injury in mice. J Radiat Res 51:73–79PubMedCrossRef

60.

Gao Z, Zhang Q, Han Y, Cheng X, Lu Y, Fan L, Wu Z (2012) Mesenchymal stromal cell-conditioned medium prevents radiation-induced small intestine injury in mice. Cytotherapy 14:267–273PubMedCrossRef

61.

Semont A, Mouiseddine M, Francois A et al (2010) Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ 17:952–961PubMedCrossRef

62.

Lorenzi B, Pessina F, Lorenzoni P et al (2008) Treatment of experimental injury of anal sphincters with primary surgical repair and injection of bone marrow-derived mesenchymal stem cells. Dis Colon Rectum 51:411–420PubMedCrossRef

63.

Saha S, Bhanja P, Kabarriti R, Liu L, Alfieri AA, Guha C (2011) Bone marrow stromal cell transplantation mitigates radiation-induced gastrointestinal syndrome in mice. PLoS One 6:e24072PubMedCrossRef

64.

Peiffert D, Simon JM, Eschwege F (2007) Epinal radiotherapy accident: passed, present, future. Cancer Radiother 11:309–312PubMedCrossRef

65.

Marchesi V, Aigle D, Peiffert D, Noel A, Simon JM (2009) Securitization of the bi-site radiotherapy activity as part of the resumption of treatments in the Hospital of Epinal by the team of Alexis Vautrin Nancy Cancer Center. Cancer Radiother 13:740–743PubMedCrossRef

66.

Choi EW, Shin IS, Park SY et al (2012) Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum 64:243–253PubMedCrossRef

67.

Von Korff M, Jensen MP, Karoly P (2000) Assessing global pain severity by self-report in clinical and health services research. Spine 25:3140–3151, Phila Pa 1976CrossRef

68.

Tan G, Jensen MP, Thornby JI, Shanti BF (2004) Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 5:133–137PubMedCrossRef

69.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef

70.

Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef

71.

Sensebe L, Bourin P (2008) Producing MSC according GMP: process and controls. Biomed Mater Eng 18:173–177PubMed

Title: Use of Mesenchymal Stem Cells (MSC) in Chronic Inflammatory Fistulizing and Fibrotic Diseases: a Comprehensive Review
Authors: Jan Voswinkel
Sabine Francois
Jean-Marc Simon
Marc Benderitter
Norbert-Claude Gorin
Mohamad Mohty
Loïc Fouillard
Alain Chapel
Publication date: 01-10-2013
Publisher: Springer US
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2013
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-012-8347-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

The Hygiene Theory Harnessing Helminths and Their Ova to Treat Autoimmunity

Tolerance and Autoimmunity in Primary Immunodeficiency Disease: a Comprehensive Review

Clinical Guidelines and Definitions of Autoinflammatory Diseases: Contrasts and Comparisons with Autoimmunity—a Comprehensive Review

Regaining Tolerance to a Self-antigen by the Modified Vaccination Technique

Vitamin D in Systemic and Organ-Specific Autoimmune Diseases

Autoinflammatory Skin Disorders in Inflammatory Bowel Diseases, Pyoderma Gangrenosum and Sweet’s Syndrome: a Comprehensive Review and Disease Classification Criteria

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials